Werbung
Werbung

MRKR

MRKR logo

Marker Therapeutics, Inc. Common Stock

2.01
USD
Gesponsert
-0.06
-2.80%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

2.04

+0.03
+1.64%

MRKR Ergebnisberichte

Positives Überraschungsverhältnis

MRKR übertreffen die 18 der letzten 26Schätzungen.

69%

Nächster Bericht

Datum des nächsten Berichts
30. März 2026
Estimate for Q4 25 (Revenue/ EPS)
$695.64K
/
-$0.20
Implizierte Änderung von Q3 25 (Revenue/ EPS)
-43.58%
/
+66.67%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
-69.11%
/
-52.38%

Marker Therapeutics, Inc. Common Stock earnings per share and revenue

On 13. Nov. 2025, MRKR reported earnings of -0.12 USD per share (EPS) for Q3 25, beating the estimate of -0.45 USD, resulting in a 73.86% surprise. Revenue reached 1.23 million, compared to an expected 737.46 tausend, with a 67.20% difference. The market reacted with a +3.48% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.20 USD, with revenue projected to reach 695.64 tausend USD, implying an increase of 66.67% EPS, and decrease of -43.58% in Revenue from the last quarter.
FAQ
For Q3 2025, Marker Therapeutics, Inc. Common Stock reported EPS of -$0.12, beating estimates by 73.86%, and revenue of $1.23M, 67.2% above expectations.
The stock price moved up 3.48%, changed from $0.89 before the earnings release to $0.92 the day after.
The next earning report is scheduled for 30. März 2026.
Based on 5 analysts, Marker Therapeutics, Inc. Common Stock is expected to report EPS of -$0.20 and revenue of $695.64K for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung